Skip to main content
Premium Trial:

Request an Annual Quote

Artemis to Provide Aventis with Genetically Engineered Mice

NEW YORK, Feb. 9 (GenomeWeb News) - Artemis Pharmaceuticals said today that it has signed a deal to use its ArteMice platform to generate genetically engineered mice for French drug maker Aventis.

 

According to Artemis, Aventis will use the mice in drug research for gene function analysis, as well as for testing novel drug candidates. Artemis said it will also provide Aventis with licenses to certain Cre transgenic mice, including the CreER-gene switch mouse, for use in in vivo gene function studies.

 

Financial terms of the arrangement were not disclosed.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.